目的:探讨结直肠恶性肿瘤术后化疗与树突状细胞(dendritic cells,DCs)细胞因子诱导的杀伤细胞(cytokine-induced killer,CIK)联合治疗临床应用价值.方法:选择结直肠癌术后化疗联合DC-CIK治疗的病人242例作为联合治疗组,将同期术后只进行化疗的病人463例作为单纯化疗组,分析联合治疗组的免疫功能激活状况以及生存质量,比较两组病人生存率差异.结果:在细胞治疗结束后一周对联合治疗组患者进行迟发性变态反应皮肤试验,结果显示57.85%患者免疫反应被激活,单纯治疗组在治疗过程中体力、食欲、睡眠和体重的变化情况,至少有2项生存质量指标改善的患者有185例(76.45%).联合治疗组和单纯化疗组病人进行为期18个月的生存率对比,联合治疗组生存率为95.04%,单纯化疗组生存率为89.63%,差异显著(P=0.016).结论:结直肠癌术后化疗联合DC-CIK治疗可以激活患者的免疫功能,改善患者的生活质量,提高生存率.%Objective: To investigate clinical application value of dendritic cells combined with cyto?kine-induced killer (DC-CIK) in the treatment of colorectal cancer. Methods Two hundred and forty-two cas?es of postoperative patients of colorectal cancer treated with chemotherapy combined with DC-CIK in Tianjin People's Hospital were selected as combined treatment group, and 463 cases of colorectal cancer treated with chemotherapy were selected as control group. The type hypersensitivity delayed (DTH) skin test was performed at the end of cell therapy. The changes of physical activity, appetite and sleep were recorded. Results In 57.85% of the patients in combined treatment group, DTH was activated. In the same group,there are 185 cases (76.45%) with at least 2 indexes of quality of life being improved. The combined treatment group and control group were compared in 18 months of survival. The survival rate of combined treatment group was 95.04%, and that of the control group was 89.63%. The difference was significant (P=0.016). Conclusion Combined DC-CIK cell therapy and chemotherapy can activate the immune function of patients, improve the quality of life, and improve the survival rate.
展开▼
